bioRxiv · 10.1101/184408
Reversal of molecular pathology by RNA-targeting Cas9 in a myotonic dystrophy mouse model
Abstract
The dominantly inherited, multi-systemic disease myotonic dystrophy type I (DM1) is caused by triplet repeat CTG expansions in the DMPK gene and is the most common form of adult-onset muscular dystrophy. Elimination of the toxic, repetitive CUG RNA constitutes a therapeutic for this disease. We report an RNA-targeting Cas9 (RCas9) system that supports efficient reversal of DM1 phenotypes via delivery to adult poly(CUG) DM1 mouse muscle using adeno-associated virus (AAV). We observe elimination of CUG RNA, restoration of CUG foci-associated Mbnl1 protein to wild-type subcellular localization, correction of DM1-type alternative splicing patterns in candidate genes including the voltage-gated chloride channel 1 (Clcn1) responsible for characteristic myotonia, recovery of Clcn1 staining, and reduction in centralized myonuclei. Our results establish RCas9 as a potential long-term in vivo therapeutic for DM1.\n\nOne Sentence SummaryA repurposed CRISPR system termed RNA-targeting Cas9 reverses the molecular pathology associated with the most common type of adult onset muscular dystrophy in adult mouse muscle.
Explore related subjects
Keep this discovery
Batra, R., Nelles, D. A., Krach, F., Thomas, J. D., Snjader, L., Blue, S. M., Aigner, S., Swanson, M. S., Yeo, G. W.. 2017-09-04. Reversal of molecular pathology by RNA-targeting Cas9 in a myotonic dystrophy mouse model. https://doi.org/10.1101/184408
Cite the original work for its findings. Save a collection to share your selection of sources.